GPCM 2013

To QbD or not to QbD? That is the Question...

Experts still out to whether QbD is a suitable route for biologics approval

Europe may soon approve the first biologic made according to quality by design (QbD) principles, but opinions are still split over whether the approach should even be applied to biopharmaceuticals.

Russian Protectionism may Offer Chances For Local CMOs, Expert Says

Russian Protectionism may Offer Chances For Local CMOs, Expert Says

Plant Design Critical in Sterile Manufacturing, Expert Says

Plant Design Critical in Sterile Manufacturing, Expert Says

Lilly: Performance Metrics Key to CMO Management

Lilly: Performance Metrics Key to CMO Management

Rising CMO costs and lower quality in India and China lead to return to West

Pharma Abandoning East, Returning West for CMOs say GPCM Delegates

Roche: Governance of CMOs Ensures Sterility, Strengthens Partnerships

Roche: Governance of CMOs Ensures Sterility, Strengthens Partnerships

Quality Most Important Factor in Selecting CMO

Quality Agreement Dictates Price in Manufacturing Relationships

'Critical' Compliance for Biologics with Nasal and Long Acting Techs

'Critical' Compliance for Biologics with Nasal and Long Acting Techs

BIg Pharma's Shift from R&D Opportunity for CDMOs, Says Expert

BIg Pharma's Shift from R&D Opportunity for CDMOs, Says Expert

Western CMOs Hold Advantages Over East, says PTI

Western CMOs Hold Advantages Over East, says PTI

More GPCM 2013